In Women Whose Breast Cancer Has Spread, Study Compares Standard Against Newer Treatm
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented by Peter A. Kaufman, M.D...
More... |
Re: In Women Whose Breast Cancer Has Spread, Study Compares Standard Against Newer Tr
Good information !!
|
All times are GMT -7. The time now is 08:17 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021